Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs - $30 Million Registered Direct Of ering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for Dementia with Lewy Bodies Ongoing - Purchase, NY – November 6, 2025 – Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical- stage company devel ...